scispace - formally typeset
I

Irene Jiménez-Munguía

Researcher at National University of Science and Technology

Publications -  31
Citations -  667

Irene Jiménez-Munguía is an academic researcher from National University of Science and Technology. The author has contributed to research in topics: Lipid bilayer fusion & Streptococcus pneumoniae. The author has an hindex of 12, co-authored 30 publications receiving 519 citations. Previous affiliations of Irene Jiménez-Munguía include University of Córdoba (Spain) & University of Veterinary Medicine Vienna.

Papers
More filters
Journal ArticleDOI

Surfomics: shaving live organisms for a fast proteomic identification of surface proteins.

TL;DR: A novel second-generation approach has been developed, consisting of the digestion of live, intact cells with proteases, so that surface-exposed moieties (i.e. the "surfome" of a cell) are "shaved" and analyzed by LC/MS/MS.
Journal ArticleDOI

Another turn of the screw in shaving Gram-positive bacteria: Optimization of proteomics surface protein identification in Streptococcus pneumoniae.

TL;DR: This work carried out the optimization of the "shaving" strategy for the Gram-positive human pathogen Streptococcus pneumoniae, a bacterium highly susceptible to autolysis, and set up the conditions for maximizing the identification of surface proteins containing sorting or exporting signals, and for minimizing cytoplasmic contamination.
Journal ArticleDOI

Exploring the pan-surfome of Streptococcus suis: Looking for common protein antigens

TL;DR: The cell-wall protein SsnA appears to be the best candidate from this list, as it was that with the widest distribution among the analyzed pathogen types, it showed to be highly immunogenic and highly accessible to antibodies, as demonstrated by flow cytometry.
Journal ArticleDOI

Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults.

TL;DR: The pan-surfomic approach shows its utility in the discovery of new proteins that can elicit protection against infectious microorganisms in humans by inducing the production of IgM antibodies in infected patients, thus indicating that they could enter the pipeline for vaccine studies.